New ESMO guidelines for clinical practice in metastatic colorectal cancer – commentary on changes in systemic therapy

Česká verzia

Authors: I. Kiss
Authors place of work: Klinika komplexní onkologické péče LF MU a MOÚ Brno
Published in the journal: Klin Onkol 2023; 37(6): 473-476
Category: Short Communication
doi: https://doi.org/10.48095/ccko2023473

Summary

Commentary on the newly released European Society for Medical Oncology (ESMO) guidelines for the diagnosis and treatment of metastatic colorectal cancer (mCRC). After 6 years, individual chapters have been updated, from molecular tumor testing to diagnostic and treatment procedures to the implementation of newly registered medicinal products. The authors highlight the most important changes in the guidelines. Awareness of possible new treatments for mCRC is important to determine the treatment strategy for patients with mCRC. In this commentary, we focus primarily on the status of systemic treatment in unresectable disease.

Keywords:

metastatic colorectal cancer – treatment – guidelines

Zdroje

1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71 (3): 209–249. doi: 10.3322/caac.21660.

2. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. [online]. Dostupné z: http: / / www.svod.cz.

3. Cervantes A, Adam R, Roselló S et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34 (1): 10–32. doi: 10.1016/j.annonc.2022.10.003.

4. Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27 (8): 1386–1422. doi: 10.1093/ annonc/ mdw235.

5. Rossini D, Antoniotti C, Lonardi S et al. Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS/ BRAF wild-type metastatic colorectal cancer: the phase III TRIPLETE study by GONO. J Clin Oncol 2022; 40 (25): 2878–2888. doi: 10.1200/ JCO.22.00839.

6. Cervantes A, Adam R, Roselló S et al. Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline. Ann Oncol 2023; 34 (1): 10–32. doi: 10.1016/j.annonc.2023.10.129.